Table 2.

Clinical characteristics and NUDT15 variants in primary ALL cases

Case n	Primary cancer	Risk group	Genetic subtypes of primary ALL	SMN subtype	Interval, y*	Cytogenetics of tMDS/AML	NUDT15 genotype†	6-MP dose, mg/m2
1	BCP-ALL	HR	—	MDS	10	Normal karyotype	WT	48
2	BCP-ALL	IR	—	Bladder cancer	24	—	HT	60
3	BCP-ALL	HR	ETV6-RUNX1	AML	3	MLL rearrangement	HT	32
4	BCP-ALL	HR	—	AML	30	45,X,-X, t(8;16;21)(q22;p11.2;q22)	HT	70
5	BCP-ALL	IR	t(1;19)	BCC	25	—	WT	47
6	BCP-ALL	HR	—	ES	9	—	WT	NA
7	BCP-ALL	HR	FUS-ERG	AML	3	NA	WT	16.6
8	BCP-ALL	SR	—	AML	8	MLL rearrangement	WT	85
9	BCP-ALL	SR	—	Neurilemmoma	12	—	WT	68
10	T-ALL	SR	—	AML	2	Normal karyotype	WT	115
11	BCP-ALL	IR	—	MDS	4	46,XX, add(3)(q26), −7, +mar	HT	60
12	BCP-ALL	HR	—	AML	4	Normal karyotype	HT	38
13	BCP-ALL	HR	MLL-AF4	OS	8	—	HT	37
14	BCP-ALL	SR	ETV6-RUNX1	MDS	1	46,XX t(5;12;17)(q35;p13;q12)	WT	27

BCP-ALL, B-cell precursor ALL; BCC, basal cell carcinoma; ES, Ewing sarcoma; HR, high risk; HT, heterozygous type; IR, intermediate risk; MDS, myelodysplastic syndrome; NA, not available; OS, osteosarcoma; SR, standard risk; T-ALL, T-cell precursor ALL; WT, wild type.

^*Time from primary cancer to SMN.

^†HT indicates heterozygous for rs116855232.